• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    UK consensus statement on safe clinical prescribing of Bexarotene for patients with cutaneous T-cell lymphoma.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Scarisbrick, J
    Morris, S
    Azurdia, R
    Illidge, Timothy M
    Parry, Eileen
    Graham-Brown, R
    Cowan, Richard A
    Gallop-Evans, E
    Wachsmuth, R
    Eagle, M
    Wierzbicki, A
    Soran, H
    Whittaker, S
    Wain, E
    Show allShow less
    Affiliation
    University Hospital Birmingham St John's Institute of Dermatology, Guy's & St. Thomas' Hospitals London Royal Liverpool University Hospital Christie NHS Foundation, Manchester Leicester Royal Infirmary Velindre Cancer Centre, Cardiff Musgrove Park Hospital Central Manchester University Hospitals, Manchester.
    Issue Date
    2012-09-10
    
    Metadata
    Show full item record
    Abstract
    Background:  Bexarotene is a synthetic retinoid from the subclass of retinoids called rexinoids which selectively activate retinoid X receptors. It has activity in cutaneous T-cell lymphoma and has been approved by the European Medicines Agency since 1999 for treatment of the skin manifestations of advanced stage (IIB-IVB) cutaneous T-cell lymphoma in adult patients refractory to at least one systemic treatment. In vivo bexarotene produces primary hypothyroidism which may be managed with thyroxine replacement. It also affects lipid metabolism typically resulting in raised triglycerides which requires prophylactic lipid modification therapy. Effects on neutrophils, glucose and liver function may also occur. These side effects are dose dependent and may be controlled with corrective therapy or dose adjustments. Objectives:  To produce a UK statement outlining a bexarotene dosing schedule and monitoring protocol to enable bexarotene prescribers to deliver bexarotene safely for optimal effect. Methods:  Leaders from UK supraregional centres have produced this consensus statement after a series of meetings and review of the literature. Results:  The statement outlines a bexarotene dosing schedule and monitoring protocol. This gives instruction on monitoring and treating thyroid, lipid, liver, blood count, creating kinase, glucose and amylase abnormalities. This statement also includes algorithms for a bexarotene protocol and lipid management which may be used in the clinical setting. Conclusion:  Clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma requires careful monitoring to allow bexarotene to be given safely at optimal dose.
    Citation
    UK consensus statement on safe clinical prescribing of Bexarotene for patients with cutaneous T-cell lymphoma. 2012: Br J Dermatol
    Journal
    British Journal of Dermatology
    URI
    http://hdl.handle.net/10541/254640
    DOI
    10.1111/bjd.12042
    PubMed ID
    22963233
    Type
    Article
    Language
    en
    ISSN
    1365-2133
    ae974a485f413a2113503eed53cd6c53
    10.1111/bjd.12042
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
    • Authors: Assaf C, Bagot M, Dummer R, Duvic M, Gniadecki R, Knobler R, Ranki A, Schwandt P, Whittaker S
    • Issue date: 2006 Aug
    • Omega-3 fatty acids as adjunctive treatment for bexarotene-induced hypertriglyceridaemia in patients with cutaneous T-cell lymphoma.
    • Authors: Cabello I, Servitje O, Corbella X, Bardés I, Pintó X
    • Issue date: 2017 Apr
    • Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
    • Authors: Väkevä L, Ranki A, Hahtola S
    • Issue date: 2012 May
    • Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
    • Authors: Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M
    • Issue date: 2002 Nov
    • Topical and oral bexarotene.
    • Authors: Schadt CR
    • Issue date: 2013 Sep-Oct
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.